Amgen (AMGN) : Trust Co Of Virginia Va scooped up 46,843 additional shares in Amgen during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Jul 15, 2016. The investment management firm now holds a total of 52,183 shares of Amgen which is valued at $8,502,176.Amgen makes up approximately 1.44% of Trust Co Of Virginia Va’s portfolio.
Other Hedge Funds, Including , Independent Portfolio Consultants boosted its stake in AMGN in the latest quarter, The investment management firm added 2,335 additional shares and now holds a total of 14,328 shares of Amgen which is valued at $2,334,461. Amgen makes up approx 0.71% of Independent Portfolio Consultants’s portfolio.Capstone Asset Management Co reduced its stake in AMGN by selling 874 shares or 0.69% in the most recent quarter. The Hedge Fund company now holds 126,606 shares of AMGN which is valued at $20,322,795. Amgen makes up approx 0.60% of Capstone Asset Management Co’s portfolio.Gateway Investment Advisers reduced its stake in AMGN by selling 6,545 shares or 1.25% in the most recent quarter. The Hedge Fund company now holds 517,128 shares of AMGN which is valued at $83,009,387. Amgen makes up approx 0.70% of Gateway Investment Advisers’s portfolio.Howland Capital Management reduced its stake in AMGN by selling 10 shares or 0.65% in the most recent quarter. The Hedge Fund company now holds 1,523 shares of AMGN which is valued at $245,355. Amgen makes up approx 0.02% of Howland Capital Management’s portfolio.Carl Domino Inc reduced its stake in AMGN by selling 150 shares or 1.66% in the most recent quarter. The Hedge Fund company now holds 8,912 shares of AMGN which is valued at $1,435,723. Amgen makes up approx 1.32% of Carl Domino Inc’s portfolio.
Amgen closed down -0.35 points or -0.21% at $162.93 with 18,15,610 shares getting traded on Monday. Post opening the session at $163.82, the shares hit an intraday low of $162.79 and an intraday high of $164 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
On the company’s financial health, Amgen reported $2.90 EPS for the quarter, beating the analyst consensus estimate by $ 0.29 according to the earnings call on Apr 28, 2016. Analyst had a consensus of $2.61. The company had revenue of $5527.00 million for the quarter, compared to analysts expectations of $5321.84 million. The company’s revenue was up 9.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.48 EPS.
Many Wall Street Analysts have commented on Amgen. Amgen was Initiated by Bernstein to “Mkt Perform” on Jun 29, 2016.
Amgen Inc. (Amgen) is a biotechnology company. The Company is engaged in discovering developing manufacturing and delivering human therapeutics. The Company’s sales and marketing forces are located in the United States and Europe. In the United States it sells its products to pharmaceutical wholesale distributors. The Company also markets certain products directly to consumers through direct-to-consumer print and television advertising as well as through the Internet. Outside the United States the Company sells its products to healthcare providers and/or pharmaceutical wholesale distributors. The Company’s products include Neulasta (pegfilgrastim)/NEUPOGEN (filgrastim) Enbrel (etanercept) XGEVA/Prolia (denosumab) ESAs (erythropoiesis-stimulating agents) Sensipar/Mimpara (cinacalcet) Kyprolis and Evolocumab among others.